Overview

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Status:
NOT_YET_RECRUITING

Trial end date:
2027-08-15

Target enrollment:

Participant gender:

Summary

This is a prospective, single arm trial in patients with 18 years with relapsed and refractory DLBCL. Aim of this study is to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab, gemcitabine, and oxaliplatin with or without polatuzumab vedotin (Pirto-R-GemOxpola) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) previously treated with covalent BTK inhibitors.

Phase:

PHASE2

Details

Lead Sponsor:

Ruijin Hospital

Treatments:

pirtobrutinib
polatuzumab vedotin